Drug Profile


Latest Information Update: 05 Nov 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Antithrombotics; Cytoprotectives
  • Mechanism of Action Antioxidants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Shock; Thrombosis

Most Recent Events

  • 17 Aug 2000 Two studies have been added to the Vascular Disorders pharmacodynamics section ,
  • 17 Aug 2000 Preclinical development for Shock in Europe (Unknown route)
  • 29 Apr 1997 A study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top